biostudies-literatureUnknown135(4)Hong X<h4>Backgrounds</h4>GALLIUM is a global phase III study that demonstrated significant improvements in progression-free survival (PFS) for obinutuzumab plus chemotherapy (G-chemo) vs. rituximab plus chemotherapy (R-chemo) in previously untreated patients with follicular lymphoma (FL). This study aimed to report the results of a subgroup of patients in China.<h4>Methods</h4>Patients were randomized to G-chemo or R-chemo. Responders received maintenance therapy for 2 years or until disease progression. The primary endpoint was investigator (INV)-assessed PFS. Secondary endpoints included the overall response rate (ORR) and complete response rate (CRR) at the end of induction chemotherapy, overall survival (OS), and safety.<h4>Results</h4>Overall, 58 patients with FL were randomized to the G-cChinese medical journal433-440https://www.ebi.ac.uk/biostudies/studies/S-EPMC8869628biostudies-literatureEfficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study.PMC8869628Kinkolykh ALi JHong XFeng JLin TGuo WWu GKnapp AZhang QSong YShi YfalseEfficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study.<h4>Backgrounds</h4>GALLIUM is a global phase III study that demonstrated significant improvements in progression-free survival (PFS) for obinutuzumab plus chemotherapy (G-chemo) vs. rituximab plus chemotherapy (R-chemo) in previously untreated patients with follicular lymphoma (FL). This study aimed to report the results of a subgroup of patients in China.<h4>Methods</h4>Patients were randomized to G-chemo or R-chemo. Responders received maintenance therapy for 2 years or until disease progression. The primary endpoint was investigator (INV)-assessed PFS. Secondary endpoints included the overall response rate (ORR) and complete response rate (CRR) at the end of induction chemotherapy, overall survival (OS), and safety.<h4>Results</h4>Overall, 58 patients with FL were randomized to the G-c2021-01-01T00:00:00Z2021 Sep2026-06-01T02:29:15.203Z2024-10-16T14:49:13.442ZS-EPMC88696283519400510.1097/CM9.0000000000001737